Lilly's abemaciclib passes latest MONARCH test

Eli Lilly and Co. (NYSE:LLY) said abemaciclib (LY2835219) significantly improved progression-free survival (PFS) in the Phase III MONARCH 3 trial to treat hormone receptor-positive, HER2-negative advanced breast cancer, meeting the study's primary endpoint. The company plans to include the data in global regulatory submissions, beginning in 3Q17.

Lilly said the selective dual inhibitor of cyclin dependent kinase 4 (CDK4) and CDK6 also significantly improved objective response rate, a secondary endpoint. Both measurements were based on a pre-planned interim analysis of MONARCH 3. Lilly said it plans to present detailed study results next half...